Sino Biopharmaceutical announced that it has entered into an exclusive license agreement with Sanofi for the drug Rovadicitinib. The short news piece from Reuters provides no further details regarding the terms or implications of this agreement.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Sino Biopharmaceutical Discloses Exclusive License Agreement For Rovadicitinib With Sanofi
Sino Biopharmaceutical announced that it has entered into an exclusive license agreement with Sanofi for the drug Rovadicitinib. The short news piece from Reuters provides no further details regarding the terms or implications of this agreement.